Latest From Mirum Pharmaceuticals
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.
The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- North America
- Company Type
- Parent & Subsidiaries
- Mirum Pharmaceuticals
- Senior Management
Chris Peetz, Pres. & CEO
Pamela Vig, PhD, CSO
Lara Longpre, Chief Development Officer
Ian Clements, PhD, SVP, Fin. & Communications
- Contact Info
Phone: (650) 667-4085
950 Tower Ln.
Foster City, CA 94404
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.